A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Psoriasis
In brief
This is a study to assess the pharmacokinetics, safety and tolerability of multiple ascending oral doses of ABBV-553 in healthy volunteers and the pharmacokinetics, safety, tolerability and efficacy of multiple ascending oral doses of ABBV-553 in participants with psoriasis under non-fasting conditions.
Key facts
- Study ID
- NCT03145948
- Run by
- AbbVie
- People needed
- 12
- Starts
- 2017-05-09
- Expected to finish
- 2017-08-16
- Last updated by the study team
- 2017-11-06
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Anaheim Clinical Trials LLC /ID# 164101 — Anaheim, California, United States
- Providence Clinical Research /ID# 163867 — Toluca, California, United States
- Progressive Medical Research /ID# 163868 — Port Orange, Florida, United States
- Abbvie Clinical Pharmacology Research Unit /ID# 163866 — Grayslake, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.